Home Old

Pausing damage during Ischemic Stroke

When treatment is a race against time, pressing pause can be the difference in preventing a lifetime of disability.

NeuraStasis protects tissue, allowing more time to intervene

Novel proprietary technology stimulates the body’s innate neuroprotective reflexes – placing neural tissue into stasis – preserving the brain and giving providers more time to act.

Preventing disability after stroke remains a persistent need

Problem

In treating acute ischemic stroke, “Time is Brain.” Damage to the brain can rapidly cause permanent disability or death without intervention.

Solution

Using proprietary noninvasive neurostimulation, NeuraStasis aims to slow down the spread of damage, protecting patients awaiting treatment.

Vision

NeuraStasis is on a mission to change the paradigm of stroke care. Everyone deserves a chance at returning to their normal lives after a stroke.

A Bridge to Care

Using non-invasive electrical stimulation, NeuraStasis is developing a
much-needed bridge to care – a way to slow the spread of ischemic damage during a
devastating medical emergency

Rapid Deployment

Designed to conform to multiple anatomies easily and begin treatment within minutes

Smart Neurostimulation

A proprietary stimulation algorithm activates brainstem reflexes to help preserve tissue

Scientific Principles

The technology is built on the principles of ischemic progression and preclinical neurostimulation research

Experienced Staff

The technology is being developed in concert with leading experts in stroke and neurovascular product development

Practical Design

The device will be capable of use in multiple care settings and transferred with patients

Expert Opinions

Nonpharmacological approaches to freeze the penumbra are particularly attractive because they are generally noninvasive and easy to administer, and thus could be initiated in the ambulance or even prehospital, in-the-field. According to the concept of freezing the penumbra, such ultra-early interventions would enhance the therapeutic effects over and above reperfusion therapy

The current high rates of successful recanalization due to tremendous advancements in MT technology render it less likely that further improvement in devices will translate to a dramatic improvement in functional outcome: effective neuroprotection could break this ceiling effect.

In most prior efforts to develop stroke therapy, an emphasis was placed on testing single-action, single-target agents. This approach ignored the fact that ischemia produces a plethora of pathological pathways proceeding both in series and in parallel. Workshop participants propose that a multiple-action, multiple-target approach for ischemic stroke could have a higher likelihood of success in patients with stroke

NIH MedTech program aims to accelerate medical devices ..

Newswise — The National Institutes of Health has awarded research funding for seven pilot projects developing early stage, yet groundbreaking ..

A DRONE’S-EYE VIEW OF THE 2022 NWA TECH SUMMIT

The Northwest Arkansas Technology Summit, self-described as “the Heartland’s premier technology conference,” returned for its ninth edition this October…